Document:

EX-10.25

 Exhibit 10.25 

 
 

 
 December 13, 2016 

Cameron Turtle 
  

	Re:	 BridgeBio Pharma Employment 

Dear Cameron: 
 BridgeBio Pharma LLC (the “Company”)
would be lucky to have you on board as a member of our team. As an outstanding performer in both the science and business realms, you bring critical perspectives that would immediately increase the value of BridgeBio and positively impact our
ability to help the patients we serve. In your role, you time would be split as follows: 
  

	 	•	 	 Initially 50% Eidos, working to lead business development and corporate strategy for the familial amyloid
cardiomyopathy program and working closely with Hoyoung (Board), me (Board, CEO) and Jonathan Fox (CMO, (he was the CMO at MyoKardia as well)). In this role, you will be expected to help us craft the corporate story, to develop and execute a BD /
partnering strategy, to support the company IPO should we decide on that route in the next 18 months, to help build our presence in the clinical and investor community, and to think through internal recruiting, budgeting, and operations). You will
also be a Board Observer at Eidos. Your title will be VP, Business Development and Operations at Eidos. 

  

	 	•	 	 50% with BridgeBio. Helping diligence assets, execute deals, and ultimately to take the lead on 1-2 deals in terms of setting up the new company and playing a founding operating role as necessary. You will report directly to me in this role. Your title will be Sr. Director of Something (we should determine the
‘something’ together depending on what your ultimate career interests are -Sr. Director of Business Development or Corporate Development to start (title to be agreed with you) 

Your effective date of hire (the “Start Date”) will be whenever you would like in Q1 of 2017 (preferably earlier in the quarter but dependent on
your bonus payout from your current employer). 
 Your compensation for this position will be at the rate of $200,000 per year. There is no bonus program in
the company as of yet, but as soon as there is, you will be a part of that with a performance target of 20%. Additionally, we would grant you an option to purchase 20,000 shares of the Company’s Interest. The exercise price of the Option will
be at least equal to the fair market value of the Company’s common stock on the date of grant, and the Board of Directors may elect to seek a third party valuation of such fair market value, which could delay

 
the date that the Option is granted. The Option will be subject to the terms and conditions of the Company’s then-current stock option plan and form of stock option agreement. These options
will vest as follows: 1/60th of the shares will vest on a monthly basis, such that 100% of such Common Units shall be vested on the 5 year anniversary. We will give you a one-time bonus as well to cover the
cost of early exercise on this option. Finally, we would grant you an option to purchase 20,000 of Eidos Therapeutics Inc stock. The exercise price of the Option will be at least equal to the fair market value of on the date of grant. The Option
will be subject to a four year vesting with a one year cliff. 
 It is understood that you are an
“at-will” employee. You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or
without cause or prior notice and without additional compensation to you. 
 In making this offer, the Company understands that you are under no obligation
to other current employers that might impair the performance by you of your duties as an employee of the Company. 
 The Immigration Reform and Control Act
requires employers to verify the employment eligibility and identity of new employees. You will be required to complete a Form I-9 which will be provided to you before the Start Date. Please bring the appropriate documents listed on that form with
you when you report for work. We will not be able to employ you if you fail to comply with this requirement. Also, this offer is subject to satisfactory reference checks if necessary. 

This letter agreement constitutes the complete agreement between you and the Company, contain all of the terms of your employment with the Company and
supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a
duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time. 

Sincerely, Neil Kumar and the BridgeBio Team 
 /s/ Neil Kumar

 I, Cameron Turtle, accept the offer terms proposed by Neil Kumar and the BridgeBio team. 

 

	
	 /s/ Cameron Turtle

	Cameron Turtle

 

 
 May 1, 2017 
 Cameron W.
Turtle 
  

	 	Re:	 Transfer of Employment 

Dear Cameron: 
 As you may know, BridgeBio Pharma
LLC (the “Company”) is in the process of transferring all of its operating assets into separate corporate entities (the “Restructuring”). As part of the Restructuring, all Company employees are being transferred to
BridgeBio Services, Inc. (“BridgeBio Services”), a newly formed subsidiary of the Company. Consequently, effective as of May 1, 2017 (the “Transfer Date”), your employment will be transferred to BridgeBio
Services on an at-will basis, and you will no longer be employed by the Company. Except as otherwise described below, the terms and conditions of your employment will remain the same. 

Payroll. Following the Transfer Date, you will be paid at the same rate and on the same schedule as before the Transfer Date, but
BridgeBio Services will begin issuing your paychecks using its Employer Identification Number. Credit for all employment taxes paid by you and the Company prior to the Transfer Date will be transferred to BridgeBio Services without any additional
action on your part. 
 Health and Welfare Benefits. Following the Transfer Date, you will be eligible to participate in an upgraded
Platinum health and welfare benefit plan than which you are currently eligible to participate, subject to their terms and conditions. You have already completed new enrollment forms, and have been informed you will not be credited for amounts you
have paid toward any deductibles and out-of-pocket maximums during the plan year prior to the Transfer Date (such amounts, the “Deductibles”). In order
to compensate for the loss of such credit, BridgeBio Services will make a cash payment to you in an amount equal to the Deductibles plus 35% which is an estimate equal to the aggregate withholding and employment taxes due by you in connection with
the Deductibles and the additional amount, such payment to be made by the end of May provided you include an EOB to support the deductible amount met to date. 

Management Incentive Units. Any Management Incentive Units (“MIUs”) previously granted to you will remain outstanding
and eligible to vest in accordance with their terms, provided that, upon your signature below, the agreement(s) evidencing your MIUs will be deemed amended to provide that your MIUs will vest based upon your continued employment with BridgeBio
Services. The terms and conditions of your MIUs will otherwise remain the same. 
 Accrued PTO. In connection with your transfer of
employment, your accrued and unused vacation days and paid time off (collectively, “Accrued PTO”) will be transferred to BridgeBio Services, and you will be entitled to use your Accrued PTO in accordance with the same policies in
effect prior to the Transfer Date. By signing this letter, you consent to the foregoing transfer of Accrued PTO to the extent necessary. 

Please indicate your agreement to the foregoing by signing in the space provided below and returning it to Lena Pang or Kristie Dang by
May 5, 2017. Should you have any questions regarding your transfer of employment, please contact Asha Rajagopal at asha@solutions-on-call.com. 

 
			
	Sincerely,
	
	BRIDGEBIO PHARMA LLC
		
	By:	 	 /s/ Neil Kumar

	Name:	 	Neil Kumar
	Title:	 	CEO

  

					
	ACCEPTED AND AGREED,
	this	 	 May 5, 2017
	 	.
	
	 /s/ Cameron Turtle

	Cameron W. Turtle

  
 2EX-10.26

 Exhibit 10.26 

 
 

 
 June 10, 2018 
 Cameron
Turtle 
 Via email 
 Dear Cameron: 

Eidos Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 

1. Position. Your initial title will be SVP, Corporate Development. You will report to the Company’s Chief Executive Officer and you shall have
such powers and duties as may from time to time be prescribed by the CEO, provided that such duties are consistent with the position of SVP, Corporate Development or other positions that you may hold from time to time. During your employment with
the Company, you will not engage in any outside employment, consulting or other business activity (whether full-time or part-time) without the Company’s written consent. By signing this letter agreement, you confirm to the Company that you have
no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 
 2. Salary. The Company
will pay you a starting salary at the annual rate of $310,000, payable in accordance with the Company’s standard payroll schedule and subject to tax-related deductions and withholdings. This salary will
be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. 
 3. Employee Benefits. You will
be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time (including, without limitation, any group health care plan and 401(k)), subject to the terms of such plans. 

4. Bonus. Compensation for this position also includes participation in the Company’s bonus plan with an annual target bonus of 30% of your annual
salary. Your bonus will be based on the Company’s overall goals as well as your individual goals. For each year during the term of this letter agreement, you will be eligible to receive a bonus (pro-rated
in the case of any partial year during which you were employed by the Company) based on a determination by the Company’s Board (or a committee thereof) regarding the Company’s achievement of its goals and your own successful performance of
your duties through the end of the applicable year. 
 5. Stock Options. Subject to the approval of the Board, you will be granted an option to
purchase 23,920 shares of the Company’s Common Stock (the “Option”), effective upon the completion of the Company’s initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933,
as amended. The exercise price per share will be determined by the Board of Directors or the Compensation Committee when the Option is granted. The Option will be subject to the terms and conditions applicable to awards granted under the Eidos
Therapeutics, Inc. 2018 Stock Option and Incentive Plan (the “Plan”), as described in the Plan and the applicable stock option agreement. The option shares will vest in equal monthly installments over the next 48 months of your continuous
service for the Company from the effective commencement date of your employment, as described in the applicable stock option agreement under the Plan in the form previously approved by the Board. 

6. Severance. In the event your employment is terminated by the Company (or its acquirer or successor) without Cause or if you resign for Good
Reason within one (1) month before or twelve (12) months after a Change in Control (as defined in the Plan), subject to you signing a general release of claims in favor of the Company that becomes irrevocable within sixty (60) days
following the termination date, you will be entitled to be paid a lump sum payment equal to six (6) months of your then-current base salary, a pro-rated bonus in accordance with Section 4 above, and
six (6) months of COBRA reimbursement for you and your dependents if you were participating in the Company’s group health plan immediately prior to the termination date and elect COBRA health continuation (the “Change in Control
Severance”). In the event you are terminated by the Company without Cause or if you resign for Good Reason other than in connection with a Change in Control as described above, subject to you signing a general release of claims in favor of the
Company that becomes irrevocable within sixty (60) days following the termination date, you will be entitled to be paid a lump sum payment equal to three (3) months of your then-current base salary, a
pro-rated bonus in accordance with Section 4 above, and three (3) months of COBRA reimbursement for you and your dependents if you were participating in the Company’s group health plan

 
immediately prior to the termination date and elect COBRA health continuation (the “Severance”). If the 60-day period following the termination
date begins in one calendar year and ends in a second calendar year, the Change in Control Severance or the Severance, as the case may be, shall be paid in the second calendar year and no later than the last day of such 60-day period. Furthermore, to the extent you become eligible for health benefits under a subsequent employer’s health plan within six (6) months of your termination date, you agree to return a pro-rated amount of the COBRA reimbursement to the Company (or its acquirer or successor) within sixty (60) days from when you first become eligible to participate in the subsequent employer’s health plan.

 7. Employee Confidentiality and Assignment Agreement. Like all Company employees, you will be required, as a condition of your employment with the
Company, to sign the Company’s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A . 

8. Background Check. The Company may conduct a background or reference check (or both). If so, then you agree to cooperate fully in those procedures,
and this offer is subject to the Company’s approving the outcome of those checks, in the discretion of the Company. 
 9. Employment
Relationship. Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with
or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. Although your job duties, title, reporting relationship, compensation and benefits, as well as the Company’s personnel
policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you). 

10. Interpretation, Amendment and Enforcement. This letter agreement and Exhibit A constitute the complete agreement between you and the Company,
contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified,
except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement
or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company will be governed by California law, excluding laws relating to conflicts or
choice of law. 
 We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept
this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Confidentiality Agreement and returning them to me. As required by law, your employment with the Company is contingent upon your
providing legal proof of your identity and authorization to work in the United States. Should you accept this offer, your start date of employment will be June 18, 2018. 

If you have any questions, please do not hesitate to contact me. 

 

	
	Very truly yours,
	
	/s/ Christine Siu
	
	Christine Siu
	Chief Financial Officer
	EIDOS THERAPEUTICS, INC.

  
 2 

 I have read and accept this employment offer: 

 

					
	 /s/ Cameron Turtle

	Cameron Turtle
			
	Dated:	 	 June 13
	 	, 2018

 Attachment 
 Exhibit A:
Employee Confidentiality and Assignment Agreement 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]